AstraZeneca sees strong ovarian cancer trial results

AstraZeneca ’s Lynparza greatly reduced the risk of ovarian cancer worsening in a phase III trial, helping the drugmaker take the lead against two U.S. rivals in the same class.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news